Thoratec Corp. expects its SHIELD II trial testing its HeartMate PHP catheter-based heart-pump in patients undergoing high-risk coronary interventions to begin enrolling patients at up to 60 U.S. sites in the third quarter of 2015.
The company announced May 26 that FDA has conditionally approved an investigational device exemption for SHIELD II and expects FDA...